All Articles
Treating cancer is not cheap, and navigating the complex world of health insurance and financial assistance can be incredibly daunting for patients facing cancer diagnoses. By assisting patients in optimizing their insurance coverage and finding external assistance programs, financial navigators can help to alleviate the financial burden of treatment; as a result, they have undoubtedly become a central component to the delivery of quality cancer care. Read More ›
By William King
Madrid, Spain—Treatment with selpercatinib (Retevmo), a highly selective and potent RET inhibitor, resulted in a statistically significant improvement in progression-free survival compared with the multikinase inhibitors cabozantinib (Cabometyx) or vandetanib (Caprelsa) in the first-line treatment of patients with advanced or metastatic RET mutation–positive medullary thyroid cancer. Read More ›
By William King
Madrid, Spain—Results from 3 phase 3 clinical trials demonstrated the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC), including ALK-positive advanced NSCLC; EGFR exon 20 insertion-mutation–positive, newly diagnosed or advanced NSCLC; and advanced RET fusion–positive NSCLC. These findings were reported during the European Society for Medical Oncology Congress 2023. Read More ›
As leaders in healthcare, these moments of exhaustion may be a regular occurrence for us and members of our team. With the year wrapping up and the busy holiday season upon us, their frequency often increases. Fortunately, there are effective strategies we can use to help reduce their impact. Read More ›
The following clinical trials represent a selection of key studies currently recruiting patients with bladder cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to one of these clinical trials. Read More ›
On November 8, 2023, the FDA approved fruquintinib (Fruzaqla; Takeda Pharmaceuticals), an inhibitor of VEGFR-1, -2, and -3, for the treatment of metastatic colorectal cancer in adults who received previous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The FDA granted fruquintinib priority review for this indication. Read More ›
On October 27, 2023, the FDA approved toripalimab-tpzi (Loqtorzi; Coherus BioSciences), a PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine chemotherapy, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma, and as a single agent for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that progressed during or after treatment with a platinum-containing chemotherapy. Read More ›
On November 16, 2023, the FDA approved the use of pembrolizumab (Keytruda; Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. The FDA granted pembrolizumab an orphan drug designation for this indication. Read More ›
On October 24, 2023, the FDA approved ivosidenib (Tibsovo; Servier Pharmaceuticals), an oral tyrosine kinase inhibitor, for the treatment of relapsed or refractory myelodysplastic syndromes in adults with a susceptible IDH1 mutation, as detected by an FDA-approved test. Ivosidenib was granted priority review and received breakthrough therapy and orphan drug designations for this indication. Read More ›
Navigating today’s healthcare system can be challenging for anyone, but for older adults, it can be especially difficult. From scheduling appointments to engaging with clinicians to interpreting health insurance coverage, trying to secure the best medical care can be overwhelming, resulting in poor clinical outcomes, emotional distress, and reduced quality of life. Read More ›